RNS Number : 3503T
OptiBiotix Health PLC
20 March 2019

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Exclusive distribution agreement for SlimBiome®

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into an exclusive agreement with DKSH International Limited ("DKSH") to distribute OptiBiotix's SlimBiome® proprietary weight management technology in Italy and Spain. Market exclusivity is linked to sales orders in order to maximise the financial return for both parties providing some surety of income for OptiBiotix over the next three years.

DKSH is a leading market expansion services provider. DKSH helps companies and brands to grow in the consumer goods, healthcare, performance materials and technology sectors. DKSH's portfolio of services includes sourcing, market insights, marketing & sales, distribution and logistics as well as after-sales services. Publicly listed on the SIX Swiss Exchange, the Group operates in 35 markets with 33,000 specialists, generating net sales of CHF11.3 billion in 2018.

The agreement continues OptiBiotix's strategy of expanding SlimBiome® and SlimBiome ® related products, such as its own GoFigure brand for weight management, into key European markets. SlimBiome® is a patented formulation developed by experts in nutrition using ingredients shown to reduce weight in human studies. Independent human studies at a number of universities have shown SlimBiome® reduces hunger and cravings for sweet, fatty and savoury foods, leading to an average 2-3lb per week weight loss.

Christina Wood, Sales & Marketing Director of OptiBiotix commented: "*We are pleased to announce the signing of this agreement with such a strong global partner focusing on the Italian and Spanish markets. With its strong Swiss heritage and long business tradition since 1865, DKSH is a highly successful global corporation with a strong positioning in both consumer goods, including foods and beverages, as well as healthcare and technology; key areas for our weight management products. We are delighted that DKSH will be bringing their marketing and sales expertise to promote the sale of SlimBiome®. With its industry awards, clinical studies demonstrating safety and efficacy, medical device registration and CE mark, we believe SlimBiome® is highly differentiated from other weight management products. We*

hope combining these attributes with DKSH's sales, marketing and distribution expertise will generate substantial revenues in the months and years ahead."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

www.optibiotix.com

OptiBiotix Health plc
Stephen O'Hara, Chief Executive — *Contact via Walbrook below*

Cairn Financial Advisers LLP (NOMAD) — Tel: 020 7213 0880
Liam Murray / Jo Turner

finnCap (Broker) — Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)

Walbrook PR Ltd — Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy — Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the

Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

AGRQKLFFKXFFBBD